When psychotherapy is helping someone get better, what does that change look like in the brain? This was the question a team of Canadian psychological scientists set out to investigate in patients suffering from social anxiety disorder. Their findin…
MADISON — Researchers may have pinpointed a reason many smokers struggle to quit. According to new research published in the journal Addiction, smokers with a history of anxiety disorders are less likely to quit smoking. The study, conducted by th…
The U.S. Food and Drug Administration has approved Effexor XR for the treatment of patients with social anxiety disorder, a condition which may affect up to 13 percent of Americans at some point in their lives. EFFEXOR XR, already approved for the treatment of depression and generalized anxiety disorder (GAD), is the first available serotonin-norepinephrine reuptake inhibitor (SNRI), and is believed to increase the levels of two key brain chemicals thought to be deficient in individuals suffering from depression and anxiety disorders.